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Available online 3 August 2016Aberrant activation of signal transduction pathways can transform a normal cell to a malignant one and can
impart survival properties that render cancer cells resistant to therapy. A diverse set of cascades have been
implicated in various cancers including those mediated by serine/threonine kinases such RAS, PI3K/AKT, and
PKC. Signal transduction is a dynamic process involving both “On” and “Off” switches. Activating mutations of
RAS or PI3K can be viewed as the switch being stuck in the “On” position resulting in continued signaling by a
survival and/or proliferation pathway. On the other hand, inactivation of protein phosphatases such as the
PP2A family can be seen as the defective “Off” switch that similarly can activate these pathways. A problem for
therapeutic targeting of PP2A is that the enzyme is a hetero-trimer and thus drug targeting involves complex
structures.More importantly, since PP2A isoforms generally act as tumor suppressors onewouldwant to activate
these enzymes rather than suppress them. The elucidation of the role of cellular inhibitors like SET and CIP2A in
cancer suggests that targeting these proteins can have therapeutic efﬁcacy by mechanisms involving PP2A
activation. Furthermore, drugs such as FTY-720 can activate PP2A isoforms directly. This review will cover the
current state of knowledge of PP2A role as a tumor suppressor in cancer cells and as a mediator of processes
that can impact drug resistance and immune surveillance.
© 2016 The Author. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
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1.1. Background
Signal transduction is a dynamic process and so components are
required to both initiate signaling and also to stop the cascade at the
appropriate time. While we have a very good understanding of many
survival kinases in cancer, the protein phosphatases that serve as the
“brakes” for most if not all cellular signaling cascades are understudied
[1]. On June 1, 2016 if you use PubMed to search for articles using
terms “serine threonine protein phosphatases cancer”, you will ﬁnd
1660 papers on this topic. In contrast, a PubMed search using terms
“serine threonine protein kinase cancer” identiﬁes 75,070 reports.
Thus for every cancer related paper involving serine threonine protein
phosphatases, there are 45 papers on kinase role in cancer. That is not
to say protein phosphatases are any less important than kinases in sig-
naling pathways. To some extent the serine threonine protein phospha-
tases are understudied because they are more difﬁcult to work with
compared to kinases. While many major kinases like Protein Kinase B
(AKT), Extracellular Signal Regulated Kinase (ERK), and Protein
Kinase C (PKC) are monomers, serine threonine protein phosphatases
like Protein Phosphatase 1 (PP1) and Protein Phosphatase 2A (PP2A)
are multimers. The subject of this review, PP2A, is a hetero-trimer.
The PP2A hetero-trimer consists of a catalytic core comprised of the A
and C subunits (the functional portion of the enzyme that is responsible
for the dephosphorylation event) as well as a regulatory B subunit that
controls substrate speciﬁcity and cellular localization [1–6]. Thus for a
proof-of-principle experiment where one might overexpress a protein
or suppress its gene expression by siRNA, shRNA, or CRISPR, one has
to account for three subunits rather than one. Further complicating
matters is the fact that each subunit in the hetero-trimer has multiple
isoforms [7–9]. There are two isoforms of the catalytic (PPP2CA aka
Cα and PPP2CB aka Cβ), two isoforms of the scaffold A subunit
(PPP2R1A aka Aα and PPP2R1B aka Aβ) and at least 17 different B sub-
unit proteins that aremembers of predominantly of three families iden-
tiﬁed as B family (aka B55; gene symbol PPP2R2), B′ family (aka B56;
gene symbol PPP2R5) and B″ family (aka PR72/130; gene symbol
PPP2R3) [7–13]. Striatins (B‴ family; gene symbol STRN) are a fourth
regulatory subunit family [1,13]. Each PP2A subunit is located on sepa-
rate chromosomes in humans. A list of the human regulatory and core
PP2A subunits that have been identiﬁed and their chromosomal
location is presented in Table 1. Though for both A and C subunits the
isoforms are N80% homologous by protein sequence, there are distinct
differences between each isoform [8,9]. For simplicity, PP2A isoforms
are identiﬁed by the B regulatory subunit they contain. The B regulatory
subunit determines the substrate speciﬁcity and cellular localization of
the resulting PP2A isoform so identiﬁcation of enzyme isoform by theseTable 1
List of PP2A subunit genes and their chromosomal location in human.
Common name Symbol Chromosome location
A α PPP2R1A 19q13.41
A β PPP2R1B 11q23.2
B55 α PPP2R2A 8p21.2
B55 β PPP2R2B 5q32
B55 γ PPP2R2C 4p16
B55 δ PPP2R2D 10q26
B56 α PPP2R5A 1q32.2
B56 β PPP2R5B 11q13
B56 γ PPP2R5C 14q32
B56 δ PPP2R5D 6p21
B56 ε PPP2R5E 14q23
PR72 PPP2R3A 3q22.1
Striatin STRN 2p22
Striatin 3 STRN3 14q12
Striatin 4 STRN4 19q13
C α PPP2CA 5q31.1
C β PPP2CB 8p12subunits is appropriate. The diversity of subunits involved in assembling
the active protein phosphatase reveals that PP2A is not a single enzyme
but rather a family of enzymes.
1.2. Regulation of PP2A expression
Mechanisms regulating gene expression of PP2A subunits are poorly
understood. Little is knownof transcription regulatingB subunit expres-
sion though the role of microRNAs (miRs) in this process is emerging
[14]. Transcription factors regulating A alpha and C alpha have been
identiﬁed [15–17]. A comprehensive analysis of transcription factors
regulating A alpha gene expression was performed and identiﬁed
CREB and SP-1 as a major regulators of the alpha scaffold gene [15]. In
hepatocellular carcinoma (HCC), a single nucleotide polymorphism
(SNP) mutation in the A alpha promoter revealed involvement of NF
kappa B [16]. Ikaros suppression of transcription of the C alpha subunit
has been reported [17]. Little if anything about how PP2A B subunit
genes are transcribed is known.
A better understanding of proteolytic regulation of PP2A B subunit
expression is known. Some PP2A B subunits are subject to proteolysis
if they are out competed for binding to catalytic core components.
Thus change in expression of one B subunit can impact expression of
another B subunit. The Virshup group demonstrated in Drosophila that
reduction of A subunit using siRNA resulted in loss of C and B subunit
expression [18]. Likewise, reduction of C subunit by siRNA resulted in
loss of A and B subunit expression. As mRNA levels of A and B subunit
were unaffected in the presence of C subunit siRNA, this suggested
that PP2A isoform expression is regulated by proteolysis [18]. Strack
and colleagues determined that proteolytic regulation of certain PP2A
B subunits also occurs in mammalian cells and degradation of some
PP2A monomers involves ubiquitin/proteasome pathway [19,20].
While B55 alpha and B56 alpha appear to be unstable as monomers,
members of the B″ family and Striatins are stable when free of the cata-
lytic core [20,21]. Hetero-trimer assembly relies on association of the B
subunit with the catalytic core [1,4,19–23]. However, PP2A isoform
speciﬁcity does not rely on the catalytic C subunit [24]. An interesting
mechanism regulating catalytic subunit stability involves its association
with the alpha 4 protein which is also known as Immunoglobulin
(CD79A) Binding Protein 1 (IGBP1). Alpha 4 binds the catalytic subunit
and prevents its poly-ubiquitination and degradation [25–29]. Alpha 4
is necessary for stability of PP2A as well as PP4 and PP6, suppresses
apoptosis, and the protein is essential for activity of all PP2A isoforms
[25–28]. The role for Alpha 4 in PP2A regulation is confusing as catalytic
subunits bound to Alpha 4 are stable but inactive [27]. Based on structural
analysis of PP2A catalytic subunit complex with Alpha 4 and comparison
with the structure of the PP2A holoenzyme, a model was proposed by
Jiang and colleagues where Alpha 4 is proposed to act as a scavenger
chaperone for monomeric PP2A C subunits [28]. The model suggests
that Alpha 4 prevents uncontrolled phosphatase activity by the C subunit.
In addition, methylation of the C subunit may be critical to displace the
catalytic subunit from Alpha 4 and promote association with the scaffold
subunit to create the PP2A catalytic core [28]. Alpha 4 may also direct
preferential B subunit association with the catalytic core under certain
physiologic conditions. For example, glutamine deprivation promotes
PP2A isoforms containing B55 alpha in an Alpha 4 dependent manner
[29].
2. B subunit proteins as the drivers of PP2A function
2.1. B55 family isoforms
While B55 family (PPP2R2 series) targets involve a broad range of
physiologic functions, a major focus of study involves the role of the
B55 alpha isoform as a stress survival protein and as a cell cycle regula-
tor [30–36]. Alpha 4 mediated activation of B55 alpha during glutamine
deprivation results in dephosphorylation and inactivation of an E3
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and suppresses p53 [29]. Interestingly, p53 plays a survival role in
this scenario as B55 alpha mediated support of p53 is required for sur-
vival of the cells during the stress of glutamine deprivation [29]. Mitotic
exit requires dephosphorylation of Cyclin Dependent Kinase 1 (CDK1),
Greatwall (GWL), and CDK1 substrates such as Histone H1 that is
mediated by B55 alpha as well as PP1 [30–34,37]. Schmitz and
colleagues determined that B55 alpha CDK1 substrates rather than
CDK1 were the essential targets for mitotic exit regulation by the
PP2A isoform [37]. While pharmacologic inhibition of CDK1 had limited
effect on indicators of mitotic exit such as nuclear reassembly and Golgi
reformation, genetic suppression of B55 alpha signiﬁcantly blocked
these processes. A key feature of this model was the interplay between
Importin 1 and B55 alpha [37]. As will be discussed later, PP2A plays
many roles in trafﬁcking proteins including nuclear proteins, For
instance, PP2A mediates the transport of GWL between the nucleus and
cytoplasm [34]. Greater details on the mechanism behind this process
will be discussed later. Cyclic adenosine monophosphate–regulated
phosphoprotein 19 (ARPP19) is a PP2A inhibitor that is activated by
GWL [30] and can also be activated by CDK1 in a GWL-independentman-
ner [31]. B55 alpha can dephosphorylate ARPP19 [32]. These processes
create an effective “On/Off” switch for mitotic exit whereby B55 alpha
PP2A inactivates GWL and ARPP19 thus allowing the cell to exit mitosis
and enter interphase. The B55 beta subunit has been shown to regulate
Cyclin E proteolysis [36]. Regulation of the cell cycle appears to involve
a complex network involving the B55 family. B55 alpha negatively regu-
lates AKT survival signaling which impacts apoptotic potential of certain
cancer cells and contributes to drug resistance [38–42]. PP2A regulation
of AKT is cell type speciﬁc as B56 family members beta and gamma has
been shown to be AKT phosphatases [43,44]. The B subunit dephosphor-
ylates AKT at threonine 308 [38,41]. B55 alpha also targets PKC alpha [42].
Reduced expression of the B subunit is associated with shorter remission
duration and tendency to relapse inAML [41]. ThemicroRNAmiR-222has
been shown to support liver cancer cell survival by activating AKT via a
mechanism that involves suppression of B55 alpha by the miR [39]. The
role for B55 alpha in cells is clearly cell type speciﬁc as the B subunit
appears to be a tumor promoter in pancreatic cancer [45]. In the study
by Hein and colleagues, increased B55 alpha was associated with
increased survival signaling including activation of ERK and increased
phosphorylation of AKT at serine 473 [45]. The discrepancy between
role of the B subunit in pancreatic cancer compared to leukemia and
lung cancer likely reﬂects the composition of the PP2A isoforms in each
of these malignant cells. For some PP2A isoforms, the enzyme's compo-
nents will thrive or be proteolyzed based onwhich competing B subunits
and catalytic cores are present [18–20]. In leukemia cells, B55 alpha and
B56 alpha directly compete for catalytic core molecules. Suppression of
B55 alpha by shRNA in leukemia induces B56 alpha while shRNA reduc-
tion of B56 alpha promotes B55 alpha expression [42,46]. B55 alpha
could potentially support B56 alpha function if catalytic core units were
present to support the formation of both PP2A isoforms. PKC alpha has
been shown to phosphorylate B56 alpha at serine 41 thereby suppressing
PP2A function [47]. B55 alpha can dephosphorylates and inactivate PKC
alpha [42]. Thus B55 alpha suppression of PKC alpha could promote B56
alpha PP2A function under certain conditions.
If B55 alpha role as tumor suppressor versus tumor promoter relies
on AKT signaling then the phosphorylation status of the kinase will be
important as threonine 308 and serine 473 phosphorylated AKT have
different functions [48]. AKT phosphorylation of mTORC1 relies on
threonine 308 and not serine 473 [48–50]. Gallay and colleagues
demonstrated that elevated AKT threonine 308 phosphorylation
and not serine 473 phosphorylation is prognostic for poor outcome
in AML [51]. Thus B55 alpha role as potential tumor suppressor in AML
may reﬂect the importance of AKT signaling regulated by threonine
308 phosphorylation in the disease.
A recent study suggests that B55 alpha is involved in negative regula-
tion of autophagy by serving as a Beclin phosphatase [52]. Interestingly, itappears this mechanism is cell type speciﬁc as the phenomenon was
observed in skeletal tissue cells but not in cells from the liver. Starvation
of skeletal cells resulted in B55 alpha dissociation form Beclin allowing
for DAPK phosphorylation of the autophagy molecule [52]. B55 alpha
may have a general role in autophagy as the B subunit targets ULK1
[53]. ULK1 is subject tomTORC1 regulation so this suggests an interesting
cross-talk between AKT/mTOR components in autophagy. The B55 alpha
subunit clearly has diverse roles in sustaining cellular homeostasis. A
scheme depicting some of the various B55 alpha targets that have been
discussed is presented in Fig. 1.
2.2. B56 family isoforms
The B56 family (PPP2R5 series) is prominent for its regulation
of molecules involved in apoptotic control including BCL2, p53, MYC,
Glycogen Synthase Kinase 3 (GSK3), the Extracellular Receptor Kinases
(ERKs), and beta catenin [46,54–62]. B56 alpha has been shown to de-
phosphorylate BCL2 at serine 70 in response to stresses associated
with ceramide production [46,55,63,64]. BCL2 phosphorylation effect
on its anti-apoptotic function is cell type speciﬁc though serine 70 phos-
phorylation is associated with optimal binding to BAX and BAK and is
associated with prognosis for poor overall survival in AML [65–68].
The B56 alpha subunit may serve a general role in support of cellular
PP2A function by assisting nuclear transport of catalytic subunitmediated
by Exportin 1 (XPO1; ref. [69]). Genetic studies to identify PP2A subunit
association with SV40 small T antigen transformation identiﬁed B56
alpha and B56 gamma as candidates [70]. B56 gamma has been impli-
cated in p53 regulation so a role for this B subunit in cellular transfor-
mation is very plausible [71–73]. B56 gamma role in tumor formation
could also reﬂect other targets of the PP2A isoform. A recent study has
identiﬁed PPP2R6 deletions in lung adenocarcinoma affecting ERK
activity [74]. The B subunit also has been shown to dephosphorylate
p27KIP1, a negative regulator of cell cycle progression that may have
tumor suppressor functions [75]. B56 gamma stabilizes p27 (via T187)
and promotes nuclear localization (via T157) suggesting the B subunit
is critical to P27 tumor suppressor function [75,76]. AKT has also been
implicated in cellular transformation processes involving B56 gamma
[77]. B56 gamma, as well as B56 beta, has been shown to be AKT phos-
phatases [43,44]. Loveday and colleagues propose that mutations in
PPP2R5B (B56 beta) and PPP2R5C (B56 gamma) may impact human
overgrowth syndromes by possibly affecting AKT signaling in these
individuals [78]. In addition to its likely role in tumorigenesis in some
cancers, B56 gamma also inﬂuences cancer cell migration via Paxillin
and other pathways [62,79,80].
Like the B55 family, the B56 family plays an important role in cell cycle
progression [81–89]. The interplay between PP2A and PP1 inmitotic pro-
cesses involves members of the B56 family [81,82]. PP2A B56 family
members serve important roles in the process of separating chromo-
somes during mitosis by controlling the timing of kinetochore assembly
and regulating spatial aspects of chromosome alignment with microtu-
bules [81,82,87–89]. B56 PP2A isoforms are required for motor-driven
movement of chromosomes to the metaphase plate by a mechanism in-
volving BUBR1 and Kinesin 14 [87]. Depletion of B56 subunits results in
impaired chromosome segregation that results from misalignment of
chromosomes and is independent of kinetochore assembly [87]. While
B55 and B56 can be functional competitors, it appears the two PP2A fam-
ilies cooperate inmitotic regulation [81,82]. Cross-talk betweenB56 alpha
and B55 alpha is depicted in Fig. 1. Grallert and colleagues describe an in-
teresting model where CDK-1 regulates a protein phosphatase relay that
involves PP1, and both B55 and B56 PP2A families [82]. Active CDK-1 sup-
presses the protein phosphatase relay and allows the cell to commit to
mitotic entry. CDK-1 phosphorylation of PP1 at threonine 316 prevents
association of PP1 with PP2A isoforms but during the metaphase/ana-
phase transition PP1 auto-dephosphorylates and is re-activated. Active
PP1 activates B55 alpha PP2A with subsequent dephosphorylation of
B56 family PP2A isoforms at serine 378 [82]. The interplay between
Fig. 1. B55 alpha and B56 alpha PP2A isoforms target a diverse set of substrates involved in cell cycle and cell survival. A number of B55 alpha and B56 alpha targets are depicted.
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family members at serine 378 members allows PP1 to associate with
each of the isoforms and dephosphorylate a variety of phospho-sites
in each of the subunits that imparts another level of regulation that
may involve a diversity of kinases [82].
The B56 family of PP2A isoforms are also critical regulators of
molecules like MYC and beta catenin whose protein stability is regulat-
ed by a complex regulatory system involving PP2A and GSK3 [90–96].
In both MYC and beta catenin, an initial phosphorylation event at one
phosphosite by a kinase like ERK, CDK1, or Casein Kinase stabilizes
the protein. However, this initial phosphorylation site primes GSK3
phosphorylation at a second site. Dephosphorylation at the original
phosphosite by a PP2A B56 isoform signals for the protein for
ubiquitination and degradation. Thorough reviews on the mechanistic
aspects of MYC and beta catenin degradation can be found elsewhere
[90,91,93,94]. In addition to regulating beta catenin protein stability,
the B56 PP2A isoforms have other roles in WNT signaling. B56 beta
has been shown to suppress WNT3a and TCF4 activation independent
of a role in destabilizing beta catenin protein [97]. However, functional
roles for B56 beta inWNT signaling is likely cell type speciﬁc as another
report found that the B subunit does regulate beta catenin stability [95].
Transgenic expression of B56 gamma using a lung speciﬁc promoter
results in neonatal death of mice [98]. Examination of lung tissue
demonstrated a loss of beta catenin in tissues suggesting that turning
off B56 gamma to allow for beta catenin induction is critical for lung
development [98]. PP2A regulation of GSK3 could impact both MYC
and beta catenin stability though this potential mechanism has not
been well studied in cancer. However, Mohan and colleagues identiﬁed
in cardiac cells that PI3K regulates GSK3 serine 9 phosphorylation via
PP2A in an AKT independent manner [99]. In studies investigating Tau
phosphorylation in Alzheimer's Disease, PP2A dephosphorylates GSK3
with B56 gamma being a potential GSK3 phosphatase [100,101].
2.3. PR72/PR130 family isoforms
The PR72/PR130 P2A isoforms (PPP2R3 series) are not as well studied
as the B55 or B56 PP2A families. PR72/PR130 represents a more evolu-
tionary divergent set of PP2A subunits compared to the B55 and B56 fam-
ily members [102]. These PP2A B subunits are unique from the otherfamilies as they have calciumbindingmotifs and calciumappears tomod-
ulate the activity of these PP2A isoforms [21,103]. PR72 has been shown
to regulate dopamine- and cAMP-regulated neuronal phosphoprotein
(DARPP-32), a PP1 regulatory subunit important for neurotransmitters
[103]. A role for PR72/PR130 B subunits in cancer is unclear though
genome screening identiﬁed the mouse ortholog of the B subunit is
altered inmouse pancreatic carcinoma [104].Mutationof glycine 90 to as-
partate (G90D) in the beta isoform of the A scaffold subunit (PPP2R1B)
eliminates binding of B56 gamma but PR72/PR130 binding is maintained
[105]. TheG90Dmutation has been identiﬁed in a number of solid tumors
and may be clinically relevant [106,107]. Perhaps PR72/PR130 is impor-
tant to maintain housekeeping PP2A function when PPP2R1B is mutated.
PR72/PR130 may have a critical function in maintenance of stem cell
pluripotency but its role may not involve protein phosphatase enzymatic
activity [108,109]. Themechanism involves binding to theWNT regulator
Naked Cuticle (NKD; ref. [108]). IQ-1, a small molecule that prevents
differentiation of murine embryonic stem cells (ESC), was shown to
work via a mechanism involving the PR72/PR130 regulation of beta
catenin/WNT pathway [109]. In that study it was demonstrated
that PR72/PR130 prevents beta catenin from switching usage from
CBP to p300. The increase in β-catenin/CBP-mediated transcription
at the expense of β-catenin/p300-mediated transcription is critical
for the maintenance of murine ESC pluripotency [108,109]. The Janssens
Laboratory has identiﬁed a novel function for PR130 in Epidermal Growth
Factor Receptor (EGFR) signaling [110]. In that study they demonstrated
that PR130 binds EGFR and SRC Homology 2 domain-containing Inositol
Polyphosphate 5-phosphatase.
2 (SHIP2). PR130 has a role in EGFR turnover by preventing degrada-
tion of the kinase in response to its ligand [110]. PR130 also supports
cancer cell migration and impedes cell adhesion by a mechanism
involving LPP (LIM Protein lipoma-preferred Partner [111]). Potential
support of metastasis along with support of WNT and EGFR signaling
suggest that PR72 and PR130 may act as tumor promoters rather than
tumor suppressors [111].
2.4. Striatin family
Striatins (STRN) are a family of 3 proteins (STRN, STRN3, STRN4) that
associate with the PP2A catalytic core and were designated as a fourth
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found to be associated with complexes that contain PP2A and kinases
such as Germinal Center Kinase III (GCKIII) family members Mammalian
Sterile 20-Like Kinase 3 (MST3) suggesting a novel signalosome structure,
the STRIPAK (STRN Interacting Phosphatase and Kinase) complex, that
contains both positive and negative regulatory elements [13,112–120].
The STRIPAK complex may be critical for stem cell differentiation as
knockout of Striatin Interacting Protein 2 (STRIP2 also known as
FAM40B) in murine embryonic stem cells impairs differentiation of
germ layers and blocks cardiomyogenesis [121]. The MST kinases play
pivotal roles in cellular homeostasis by controlling cell proliferation,
cell death, and other processes [122]. Therefore, the presence of
Striatins in the STRIPAK complex can serve as brakes for MST mediated
signaling [13]. In that sense the Striatinsmay be part of a signaling rheo-
stat in signal transduction pathways where STRIPAK complexes are
involved.
3. Function and role in cancer
3.1. Regulation of function
Regulation of PP2A function is complex and involves a diversity
of players including post-translational modiﬁcation of subunits, non-
PP2A cellular and viral proteins such as SET and SV40 small T antigen,
second messenger molecules such as ceramide, and gene regulatory
agents such as microRNAs. Phosphorylation, methylation, and other
modiﬁcation catalytic core subunits inﬂuences binding afﬁnity of the B
subunits and thus modulates PP2A function [4,5]. Phosphorylation of B
subunits can affect sub-cellular localization of the PP2A isoform,
inﬂuence association with the catalytic core or non-PP2A proteins,
and these modiﬁcations may inﬂuence substrate selection by the
PP2A isoform. As discussed earlier, serine 378 phosphorylation interferes
with B56 family association with PP1 [82]. PP1 was postulated to be a
general B56 PP2A protein phosphatase that can reverse phosphorylation
of multiple phosphorylation sites in B56 subunits that are introduced by
a number of kinases including CDK-1, PLK-1, mitogen activated kinases
(MAPKs), and Aurora B kinase [82]. It is thought many of these modiﬁca-
tions are important for the myriad of roles B56 PP2A isoforms play in cell
cycle. Phosphorylation of B56 alpha is important for its role in apoptosis as
a BCL2 phosphatase [46]. When B56 alpha is phosphorylated at serine 28
by dsRNA Dependent Protein Kinase (PKR), the B subunit re-localizes
from the nucleus to the mitochondria and dephosphorylates BCL2 at
serine 70 thereby reducing the full and potent anti-apoptotic function of
BCL2 [46]. Low and colleagues have found that nitration of B56 delta at
tyrosine 289 results in impaired PP2A dephosphorylation of BCL2 at
serine 70 [123]. Thus cellular homeostasis depends on the cell having
the appropriate PP2A isoforms with the required subunit modiﬁcations
to regulate the signaling cascades that are essential for its cell type. Vari-
ation in PP2A isoform stoichiometry or changes in subunit modiﬁcations
can induce aberrant activation of any number of signal cascades that
could promote tumorigenesis or support drug resistance in cancer cells.
3.2. PP2A and tumorigenesis
Suppression of the PP2A family to promote global activation of cellu-
lar kinases can be achieved by targeting the catalytic core. Perhaps the
best example of PP2A role in tumorigeneis involves transformation of
cells by chemical inhibitors of PP2A including okadaic acid and viruses
such as polyoma or SV40 [124–132]. PP2A was identiﬁed as a tumor
suppressor when it was found that malignant transformation of cells
by polyoma viruses involved the enzyme [70,126,132]. Simian Virus
40 (SV40) small T (ST) antigen and Murine Polyoma Virus middle T
(MT) antigenwere found to displace B subunits from the PP2A catalytic
core thereby suppressing function. Recent studies have shown that MT
can bind Yes Associated Protein (YAP) and when complexed with PP2A
the transcription regulator is dephosphorylated [133,134]. In additionokadaic acid class of PP2A inhibitors were found to be carcinogenic
[127,131]. These studies veriﬁed a role for PP2A dysregulation in tumor-
igenesis though a mechanism for transformation was not clear. The
Hahn laboratory investigated the mechanism how PP2A contributes to
SV40 mediated cellular transformation [77,133,135,137]. Expression of
the A alpha subunit (PPP2R1A) was modulated in host HEK cells using
increasing titer retroviral shRNA to examine contribution of this scaffold
subunit [77]. Cells with greatly reduced expression of the PP2A subunit
(i.e. N67% reduction) died by apoptosis. Cells with ~50% reduction of A
alpha became anchorage independent, were tumorigenic in mice and
resembled cells that expressed SV40 ST [77]. PP2A A beta is involved
in cell differentiation mediated by AKT so disruption of A beta containing
PP2A isoforms could also prove tumorigenic [138]. The A beta scaffold
subunit has also been shown to be involved in dephosphorylation and in-
activation of the transformation function of the RAS GTPase RalA [137].
RalA has been shown to be a critical component of RAS mediated cell
transformation and supports metastasis (reviewed in ref. [139]). The
identiﬁcation of PPP2R1B mutations in lung and colon cancer supports
this notion [107]. These ﬁndings reveal the requirement for proper
balance of PP2A activity within cells with reduced activity promoting
transformation but aminimal level of PP2A activitymust bemaintained
for survival.
3.3. Cellular inhibitors of PP2A as tumor promoters
Tumorigenic properties of transforming viruses rely on PP2A
inhibition by proteins like the SV40 small T antigen [32,136,137].
Cellular proteins like Cancerous Inhibitor of PP2A (CIP2A) and Inhib-
itor 2 of PP2A (I2PP2A; better known as SET) are emerging as key
players in cancer cell survival and drug resistance [140–145]. CIP2A
binds PP2A thus diminishing protein phosphatase catalytic activity
though the exact mechanism how CIP2A achieves this suppression is
not clear [141]. CIP2A is tumorigenic with a number of oncogenes in-
cluding MYC being targets [141,146]. Juntilla and colleagues found
that overexpression of CIP2A transformed mouse embryonic ﬁbro-
blasts (with inclusion of mutant RAS V12) as well as HEK-TERV
cells [146]. One consequence of CIP2A overexpression was MYC sta-
bilization. These results suggested that CIP2A could serve as a means
of suppressing PP2A to promote malignant transformation of cells.
To determine physiologic relevance of CIP2A overexpression in can-
cer, Junttila and colleagues surveyed expression of the PP2A inhibitor
in human head and neck cancer and colon cancer and found CIP2A
gene and protein expression was signiﬁcantly elevated in both can-
cers [146]. Subsequent studies have shown CIP2A expression is ele-
vated in many cancers [141]. Elevated expression of CIP2A is
associated with prognosis for poor survival in solid tumor cancers
and various leukemias [141,147–151]. The important players in
CIP2A mediated tumor promotion are just emerging. MYC mediated
transcription as well as MYC ampliﬁcation in breast cancer is highly
correlated with CIP2A suggesting that at least in that malignancy
CIP2A activation of the MYC oncogene is important [151].
SETwas identiﬁed as a PP2A inhibitor associatedwith acutemyeloid
leukemia cells [152]. The RNA binding protein hnRNP A2 was shown
to bind and activate SET, suggesting that overexpression of the hnRNP
protein could stimulate survival signaling by suppressing PP2A via SET
in cancer cells [153]. Another RNA binding protein, hnRNP A1, has
been shown to positively regulate SET gene expression in chronic
myeloid leukemia [154]. An interesting model of SET regulation by
sphingolipids has been developed by the Ogretmen group [143,155].
Ceramides, sphingolipid second messenger molecules associated with
anti-proliferation and anti-survival signaling, binds and inactivates SET
protein [155]. This mechanism suggests that ceramide-mediated
apoptosis could involve re-activation of PP2A at least in some cancer
cell types. Supporting this notion, the sphingosine analog FTY-720 can
potently suppress SET, re-activates PP2A, and induces cell death in
many types of cancer [40,142,144,145,156–163]. The Perrotti group
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tumorigenic function in chronic myeloid leukemia (CML) and
Philadelphia chromosome positive (pH+) acute lymphoblastic
leukemia (ALL; refs [140,142,154,157,159]). SET has emerged as a
critical target for CML therapy as SET activation is important in
blast crisis CML and SET plays a role in Tyrosine kinase inhibitor (TKI)
resistance [140,142,154,159]. Janus Kinase (JAK) is another important
regulator of SET suggesting that other oncogenic kinases may be impor-
tant in SET mediated suppression of PP2A. JAK2 promotes PKC mediated
phosphorylation of SET at serine 9 that inﬂuences its sub-cellular localiza-
tion [161]. Spingosine Kinase (SK), which is responsible for production of
the ceramide antagonist sphingosine 1-phosphate, has been shown to
support BCR-ABL protein stability by a PP2A dependent mechanism
[163]. These studies reveal a rather complicated regulatory mechanism
involving the SET/PP2A axis that contributes to tumorigenesis and drug
resistance.
3.4. PP2A mutations in cancer
An initial mutation analysis of PP2A mutations in lung, breast, and
melanoma cancers by Calin and colleagues revealedmutations occurred
in both scaffold A subunit alpha (PPP2R1A) and beta (PPP2R1B) albeit at
low frequency [106]. In that study, mutations in the A beta subunit were
mostly exon deletions attributed to abnormal splicing while A alpha
subunit mutations were generally conversion of nucleotides including
the glutamate (E) 64 [106]. The ability of E64 mutation to suppress
potential PP2A tumor suppressor activity was determined PPP2R1A
mutant E64D knock-in mice which are more prone to develop lung
carcinoma in response to benzopyrene compared to mice with wild-
type A alpha subunit expression [164]. The E64D PPP2R1A mutation
was shown to block binding of B56 family but not B55 family or PR72/
PR130 subunits to the A alpha scaffold [165]. The frequency of A alpha
mutations was also found to be low in glioma; however, almost half of
glioma samples had A alpha protein expression levels that were 10
fold less compared to counterpart cells [166]. Unlike glioma, PPP2R1A
mutations are fairly common in uterine cancers. Whole exome
sequencing and DNA copy number analysis of seventy six uterine
serous carcinoma samples revealed nearly 20% of patients contained
somatic mutation of the A scaffold subunit PPP2R1A; ref. [167]).
PPP2R1Amutations vary greatly between ovarian and uterine cancer
and mutation frequency depends on the grade of the disease [168,169].
While PPP2R1A mutations are prevalent in high grade uterine cancer,
mutations of the A subunit are rarer in high grade ovary cancer. The
differences in PPP2R1A mutation frequency in these malignancies
clearly demonstrate that they are different diseases [168,169]. A
number ofmutations in ovarian and uterine cancer have been identiﬁed
including tryptophan (W) 257 conversion to glycine (G; refs. [167–170]).
A recent study of the biological effect of theW257G PPP2R1Amutation in
ovarian cancer revealed the mutation promoted cell migration using
in vitro assays [170]. The A scaffold subunit with W257G lost the
ability to bind B56 subunits with the exception of B56 delta. Cells
with PPP2R1AW257G mutation displayed increased phosphorylation of
SRC, JNK, and JUN [170]. Inhibition of SRC or JNK with pharmacological
inhibitors suppressed cell migration in the cells with W257G mutation
suggesting that the PPP2R1A mutation affects this process via a SRC/
JNK/JUN axis [170].
PP2A A beta mutations like A alpha mutations alter association with
other PP2A subunits [137,171,172]. Based on mutations identiﬁed in
lung and colon cancer, the PPP2R1Bmutations were shown to have vari-
ous effects. Interestingly, oneAbetamutation at aspartate (D) residue540
(D540G) was found to actually bind more tightly to the catalytic subunit
and B56 B subunits compared to wild—type A beta subunit [171]. This
mutation raises the interesting possibility that the PPP2R1B D540G
mutation is a gain of function mutation that skews binding of B subunits
from A alpha toward A beta with consequences that might favor tumor
formation.One of the ﬁrst PP2A subunit mutations reported was a mutation in
the C alpha subunit in okadaic acid resistant Chinese hamster ovary cells
[173]. Mutations in either the C alpha (PPP2CA) or C beta (PPP2CB)
genes in human have not been reported. However, the PPP2CB gene
is located in chromosome 5 q and loss of the C beta subunit has
been reported in myelodysplastic syndrome (MDS) where 5q is
deleted [174–176]. Lenalidomide has been shown to be an inhibitor
of PP2A and part of its efﬁcacy in MDS patients with 5q deletion
might be the loss of PP2A function in malignant cells that are
haplo-deﬁcient PP2A C beta subunit [174–176].
Reports on mutations in the PP2A B subunits are increasing with
more extensive genome sequencing strategies in many of the major
medical centers around the world. A number of different mutations in
the B56 gamma (PPP2R5C) subunit have been identiﬁed in various
cell lines derived from solid tumors including melanoma, lung cancer,
and embryonic carcinoma [73]. Nobumori and colleagues utilized
these various mutations to determine the consequence of each muta-
tion on PP2A B56 gamma isoform structure and function [73]. A number
of mutations affected the ability of the B subunit to bind to the catalytic
core and interestingly these mutations were scattered throughout the
PPP2R5C amino acid sequence (C39R, E164K, Q256R, and L257R; ref.
[73]). Two mutations were found to allow association of the B subunit
with the catalytic core but binding to p53 substrate was lost. The
A383G and F395C mutations lie in the B subunit region where p53
binds and thus ability to dephosphorylate p53 is lost [73,177]. Interest-
ingly, one mutant (S220) lost ability to bind an as yet identiﬁed sub-
strate. The S220 mutation suppresses B56 gamma tumor suppressor
function and thus suggests that B56 gamma can act as a tumor suppres-
sor by both p53 dependent and p53 independent mechanisms [73].
Mutations of the B55 alpha (PPP2R2A) genehave been reported in pros-
tate cancer [178]. In Mutations of various B56 family members have
been found in individuals with intellectual disability and in patients
with overgrowth disorders [179,180].
3.5. PP2A and drug resistance
Dysregulation of PP2A by the various mechanisms described above
could result in aberrant survival signaling and thus impart survival
advantages to malignant cells. A recent study determined that reduced
PP2A activity accounted for Bromodomain Containing 4 (BRD4)
hyperphosphorylation that was associated with resistance to JQ1 and
other BET Bromodomain inhibitors in triple negative breast cancer
(TNBC; ref. [180]). BRD4kinase (i.e. Casein Kinase II) activitywas similar
in counterpart and TNBC cells so reduced PP2A was suggested. Reduc-
tion of PP2A catalytic subunit resulted in increased phosphorylation of
BRD4 with increased cell resistance to JQ1 [180]. Use of phenothiazine
(a PP2A activator) reduced phosphorylation and sensitized cells to the
BET Bromodomain inhibitors. PP2A regulation of BRD4 appears to
be important for JQ1 resistance in breast cancer though the B subunit
driving the BRD4 phosphatase was not identiﬁed [180]. AKT is
a major component in survival signaling inmany cancers including leu-
kemia [181–183]. In pancreatic cancer, reduced expression of the HEAT
repeat-containingprotein 1 (HEATR1) is associatedwith chemoresistance
[184]. HEATR1acts to promote PP2Amediated dephosphorylation of AKT
in pancreatic cancer cells by a mechanism involving B55 beta. Reduction
ofHEATR1 in pancreatic cancer cells renders cells resistant to gemcitabine
[184]. In colorectal cancer, B55 beta expression is reduced via an
epigenetic mechanism [185]. B55 beta negatively regulates AKT in
colorectal cancer cells though the mechanism involves targeting
the AKT kinase Phosphoinositide Dependent Kinase 1 (PDK1).
Reduced PP2A B55 beta promotes rapamycin resistance in the cancer
cells in a PDK-1 dependent, AKT independent mechanism that
involves MYC [185]. Active AKT is associated with prognosis for
poor survival outcome in AML [51,183]. Reduced expression of B55
alpha in AML cells was found to correlatewith increased AKTphosphor-
ylation, shorter remission duration, and greater tendency toward
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multiple survival pathways is associated with increasingly worse
survival outcome [183]. Since B55 alpha acts to target both AKT and
PKC alpha in AML cells, dysregulation of this B subunit impacts multiple
survival pathways [42].
Cellular PP2A inhibitors have been shown to have important roles in
drug resistance. Activation of PP2A to reverse resistance to Gleevac and
other tyrosine kinase inhibitors (TKIs) has been achieved in CML using
the SET activating drug FTY-720 [140,142,144,159,160,186]. CIP2A also
plays diverse roles in drug resistance in various cancers. CIP2Amediates
resistance to doxorubicin [187]. CIP2A plays a role in PP2A-mediated
regulation of MYC which is central in drug resistance mechanisms in
many cancers [146,151,188–190]. Consequences of CIP2A stabilization
of MYC are complex and impact many survival pathways that contribute
to drug resistance including mTOR signaling [190]. CIP2A supports MYC
stability by blocking PP2A mediated degradation [191,192].
The B56 alpha PP2A isoform is involved in MYC degradation [93].
Considering that B56 alpha also negatively regulates BCL2 anti-apoptotic
function and beta catenin stability, the B56 alpha PP2A isoform can
impact many survival pathways [46,55,93,95]. B56 alpha PP2A isoform
plays a role in drug resistance in ALL [46,55]. Knockdown of B56 alpha
by shRNA renders cells resistant to etoposide, a drug commonly used
for ALL therapy [55]. Localization of the B subunit is also important for
its role in drug resistance. Overexpression of wild type B56 alpha
sensitizes human ALL derived REH cells to etoposide but exogenous B56
alpha with mutant serine 28 converted to alanine (S28A) failed to sensi-
tize cells to the drug at low dose and was less effective augmenting
etoposide-induced killing at high dose [55]. While wild type B56 alpha
is re-localized to the mitochondria in response to drug challenge, the
S28A B56 alpha mutant did so poorly. Thus sub-cellular localization of B
subunitsmay determine if a PP2A isoform acts to support stress signaling,
have neutral effect, or oppose stress signaling depending onwhere in the
cell the enzyme is localized.
Notch regulation of PP2A may be important in gamma secretase
inhibitor (GSI) resistance in PTEN null T-ALL [191,192]. GSI inhibition of
NOTCH promotes AKT activation by a mechanism involving suppression
of PP2A [191]. It was postulated that gene expression of PP2A subunits
could be affected by loss of NOTCH. Introduction of dominant negative
Mastermind Like 1 (MAML1; a co-activator of NOTCH) into Jurkat cells
induced AKT phosphorylation similar to when Notch was suppressed
suggesting that loss of NOTCH transcription was necessary for induced
AKT phosphorylation. However, gene and protein expression of B
subunits associated with AKT dephosphorylation or catalytic core PP2A
subunits were not changed suggesting NOTCH transcription of PP2A
subunits was not involved [191,192]. Dominant negative MAML1 or
NOTCH knock down also activated AMPK which is antagonized by AKT
so effects on PP2A substrate interaction were postulated [191]. The
example of NOTCH regulation of PP2A demonstrates the complexity of
PP2A regulatory pathways.
3.6. Therapeutic strategies to target PP2A when it acts as tumor promoter
Studies with the PR72/PR130 subunits reveal that these PP2A
isoforms support pro-survival signaling and metastasis (discussed
in Section 2.3; refs. [110,111]). At least for these B subunit family
members, there could be clinical beneﬁt to inhibiting their function.
The List group has found that at least part of themechanism of action
of lenalidomide killingMDS cells with 5q deletion involves suppression
of PP2A activity [174–176]. PP2A is required for normal cellular func-
tions so cells with reduced C beta catalytic subunit due to 5q deletion
would be sensitive to an inhibitor that targets PP2A catalytic activity.
A non-toxic PP2A inhibitor, LB100, has been developed that has
shown efﬁcacy in a variety of solid tumors [193–197]. Wei and
colleagues demonstrated that LB100 or reduction of A alpha scaffold
subunit sensitized pancreatic cell lines to radiation via mechanisms
involving disruption of DNA repair [194]. CDC25 emerged as a criticalPP2A target that was affected by LB100. LB100 was shown to sensitize
ovarian cancer cells to cisplatin by a mechanism that involves at least
in part the disruption of cell cycle checkpoint regulation [195]. LB100
augments mitotic catastrophe in radiation treated glioblastoma cells
[196]. The Sablina Laboratory has demonstrated that reduced levels of
B55 alpha in lung cancer cells was associated with increased phosphor-
ylation of ATM and reduced levels of BRCA1 and RAD51 [198]. Cellswith
reduced B55 alpha were sensitive to PARP inhibitors as these cells were
less efﬁcient at DNA repair. These examples suggest that targeting PP2A
can have therapeutic beneﬁts in certain malignancies.
4. PP2A in the microenvironment
4.1. PP2A, metabolism, and TGF beta
The tumor microenvironment can be considered as the collection of
cell types that contribute to the malignant state that include the tumor
cells themselves, stromal cells, support cells such as tumor associated
ﬁbroblast and tumor associatedmacrophages, immune cells, inﬂamma-
tory cells and any other cells that provide support for the tumor. It is not
hard to imagine that as a master regulator of diverse cellular processes,
PP2A will play some role in events that we associate with the microen-
vironment such as metabolism, metastasis, immune suppression, and
stromal induced survival of tumor cells. PP2A appears to have an impor-
tant role in regulation of cancer cell metabolism [199,200]. A model has
been postulated whereby metabolic changes in cancer cells alters PP2A
methylation leading to suppressed dephosphorylation of important
enzymes such as pyruvate kinase [199]. A recent study has suggested
that overexpression of eukaryotic Elongation Factor-2 kinase (eEF-2K)
regulates the Warburg Effect in cancer cells by a mechanism involving
PP2A andMYC [200]. The eEF-2 protein induces PP2A A subunit expres-
sion when active resulting in suppression of MYC but active eEF-2K
blocks this function leading to enhancedMYC expression and increased
pyruvate kinase M2 activity [200]. PP2A appears to have a role in the
hypoxic tumor microenvironment though whether the PP2A isoforms
act as tumor suppressors or tumor promoters seems to be dependent
on the type of cancer [197,201,202]. At least in liver cancer, use of a
PP2A inhibitor (i.e. LB100) sensitizes cells to sorafenib in hypoxic condi-
tions [197]. The mechanism of PP2A mediated survival during hypoxia
in hepatocarcioma appears to involve suppression of SMAD3 phosphory-
lation which supports SMAD3 mediated expression of BCL2 [197]. It is
possible the differences in PP2A role in hypoxia induced survival signaling
in various cancers will depend on re-localization of PP2A subunits.
Surprisingly the role of PP2A in the tumor microenvironment is
understudied though some work has been done on PP2A role in TGF
beta mediated signaling [203–206]. TGF beta role in cancer is complex
with the molecule demonstrating both tumor suppressor and tumor
promoter functions depending on cell type and context [205,207,208].
The cytokine can induce signaling by SMAD-dependent and SMAD-
independent pathways with various PP2A family members being in-
volved in both arms [203–206]. TGF beta-induced SMAD2 phosphoryla-
tion is regulated positively by B55 alpha but negatively by B55 delta
[203]. Neither PP2A family member acts directly on SMAD2. B55 alpha
and B55 delta PP2A isoforms target different phosphorylation sites with
the B55 alpha stabilizing Activin-Like Kinase 4 (ALK4) while B55 delta
destabilizes the kinase [203]. Hypoxia induced PP2A mediated dephos-
phorylation of SMAD3 but not SMAD 2 resulting in nuclear localization
of SMAD3 though the B subunit involved was not identiﬁed [204]. A
role for B56 alpha in modulating TGF beta response has been suggested
by Zhang and colleagues [205]. TGF beta signaling can have pro-survival
or pro-apoptotic consequences depending on the cellular context. The
model suggests that in early cancer cells TGF beta via the Type I TGF
beta receptor recruits B56 alpha to suppress ERK activation resulting in
an anti-tumor effect. However, in advanced cancers, B56 alpha induction
is lost, ERK remains active, and TGF beta signaling has pro-survival
consequences [205]. The role of PP2A in TGF beta signaling is complex
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cascade. The effect of TGF beta on B56 alpha and B55 alpha are depicted
in Fig. 2.4.2. PP2A and immune regulation
Currently, there is great excitement about immune based cancer
therapies. Diverse strategies to activate the patient's immune system
to activate a “host versus tumor” effect include use of vaccines against
cancer antigens, monoclonal antibodies against T cell andNK cell check-
point regulators (e.g. mAbs targeting PD-1 and CTLA4), autologous CAR
T cell and CARNK cells, aswell as agents that target immunosuppressive
molecules such as arginase [209–211]. PP2A has been found to play a
critical role in regulatory mechanisms that control function of T cells,
NK cells and myeloid derived suppressor cells (MDSC) [212–226]. SET/
PP2A axis is critical for regulation of NK cell function including produc-
tion of cytokines such as interferon gamma [212,214]. As PP2A family
has many targets, there are a myriad of potential mechanisms how
the protein phosphatase can inﬂuence immune cells. Interestingly,
PI3K/AKT axis appears to be a central node in signaling that supports
immune activity and blocks resistance in T cells and NK cells [213,222,
226]. A number of studies suggest that PP2A regulation of immune
function involves control of AKT in the immune cells [213,222,223,
226]. Checkpoint inhibitors against CTLA4 and PD-1 have shown efﬁcacy
in treatment of solid tumors including melanoma and are being
developed for leukemia therapy [209–211]. In T cells, PD-1 and
CTLA4 are expressed on the cell surface and suppress AKT mediated
signaling upon ligation with their associated ligand (PD-L1 or PD-
L2 for PD-1 and CD28 for CTLA4). CTLA4 works to suppress AKT directly
via direct activation of PP2A though the mechanism is not clear [227]. A
recent report from the Westermarck group used CIP2A deﬁcient mice to
demonstrate that the PP2A inhibitor is necessary for the immuneadaptive
response [225]. Furthermore, mice lacking CIP2A had reduced levels of
CD4 and CD8 effector T cells. Roles of PP2A in T cell function relative to
the immune cell and the target cancer cell are depicted in Fig. 3,
respectively.Fig. 2. B55 alpha and B56 alpha PP2A isoforms play important roles in TGF beta signaA recent paper from Apostolidis and colleagues determined that
PP2A is required for T regulatory cell immune suppressor function by a
mechanism involvingmTOR [217]. In that study the investigators deleted
A alpha scaffold in T regulatory cells inmice by crossing Fox3pYFP-Cremice
with PPP2R1Aﬂox/ﬂox mice. Mice with T regulatory cells lacking PP2A A
scaffold developed severe autoimmunity with increases in both CD4+
and CD8+ T cells [217]. CD4+ cells produced greater levels of IL-2 and
IL-17 while CD8+ cells produced higher levels of interferon gamma
compared to control mice. If T regulatory cells expressed at least half of
PP2A A alpha compared to control then autoimmunity was not observed.
This ﬁnding emphasizes the importance of PP2A in the T regulatory cell
function [217]. Interestingly, PP2A activation in T regulatory cells is linked
to ceramide metabolism. FoxP3 was shown to suppress expression of
SMS1, an enzyme that converts ceramide to sphingomyelin [217]. The
accumulation of ceramide in T regulatory cells was suggested to suppress
SET protein, whichwas found to be positively regulated by T cell receptor
(TCR), as well as blocking tyrosine phosphorylation of the catalytic C
subunit [217]. The study did not look at B subunit involvement so it
would be interesting to see if ceramide sensitive B subunits such as
B56 alpha are prominent in T regulatory cells and if these B subunits
are essential for T regulatory cell suppressor function.
5. Conclusions
PP2A isoforms serve diverse roles in cancer cells. These enzymes can
act either as tumor suppressors or tumor promoters depending on the
cellular context. Though understudied in cancer, interest in PP2A
isoform role in cancer biology is growing. A better understanding of
PP2A regulation in cell cycle, cell growth, cell survival, and immune
response gives us a greater appreciation of the important role these
enzymes play in tumorigenesis, drug resistance, and cancer cell cloaking
against immune surveillance. Viral PP2A inhibitors like SV40 small t
antigen have been shown to play a pivotal role in viral transformation
of cells. The cellular PP2A inhibitors SET and CIP2A are frequently found
to inﬂuence drug resistance and cancer cell survival in many cancers.
Therapeutic strategies to suppress these proteins and re-activate PP2A
are being developed for the next generation of cancer therapies.ling. A model of B55 alpha and B56 alpha role in TGF beta signaling is depicted.
Fig. 3. PP2A isoforms regulate processes that impact immune function. Amodel of PP2A response to checkpoint inhibitors CTLA-4 and PD-1 in T cell is depicted in the top panel. Amodel of
PP2A regulation of checkpoint ligand PD-L1 expressed in tumor cells is shown in the bottom panel.
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